Legros, Laurence

Evaluation of residual disease and TKI duration are critical predictive factors for molecular recurrence after stopping imatinib first-line in chronic phase CML patients

Nicolini, F. E., Dulucq, S., Boureau, L., Cony-Makhoul, P., Charbonnier, A., Escoffre-Barbe, M., Rigal-Huguet, F., Coiteux, V., Varet, B., Dubruille, V., et al. (2019) · Clinical Cancer Research

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 111

The PRKAA1/AMPKα1 pathway triggers autophagy during CSF1-induced human monocyte differentiation and is a potential target in CMML

Obba, S., Hizir, Z., Boyer, L., Selimoglu-Buet, D., Pfeifer, A., Michel, G., Hamouda, M.-A., Gonçalvès, D., Cerezo, M., Marchetti, S., et al. (2015) · Autophagy

Autophagy in Disease and TherapyCalcium signaling and nucleotide metabolism

Cited by 100

European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission

Mahon, F.-X., Pfirrmann, M., Dulucq, S., Hochhaus, A., Panayiotidis, P., Almeida, A., Mayer, J., Hjorth-Hansen, H., Janssen, J. J. W. M., Mustjoki, S., et al. (2024) · Journal of Clinical Oncology

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 71

Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients

Rousselot, P., Mollica, L., Guilhot, J., Guerci, A., Nicolini, F. E., Etienne, G., Legros, L., Charbonnier, A., Coiteux, V., Dartigeas, C., et al. (2021) · British Journal of Haematology

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 46

Efficacy and safety of nilotinib in chronic myeloid leukaemia patients who failed to achieve a treatment‐free remission period after imatinib discontinuation: Results of the French Nilo post‐ STIM study

Dulucq, S., Rigal‐Huguet, F., Nicolini, F. E., Cony‐Makhoul, P., Escoffre‐Barbe, M., Gardembas, M., Legros, L., Rousselot, P., Liu, J., Rea, D., et al. (2023) · British Journal of Haematology

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 22

Kinetics of early and late molecular recurrences after first-line imatinib cessation in chronic myeloid leukemia: updated results from the STIM2 trial

Dulucq, S., Nicolini, F. E., Rea, D., Cony-Makhoul, P., Charbonnier, A., Escoffre-Barbe, M., Coiteux, V., Lenain, P., Rigal-Huguet, F., Liu, J., et al. (2022) · Haematologica

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 17

Onset of blast crisis in chronic myeloid leukemia patients in treatment-free remission

Dulucq, S., Hayette, S., Cayuela, J.-M., Bauduer, F., Chabane, K., Chevallier, P., Cony-Makhoul, P., Flandrin-Gresta, P., Jeune, C. L., Bris, Y. L., et al. (2022) · Haematologica

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 14

First-line second generation tyrosine kinase inhibitors in patients with newly diagnosed accelerated phase chronic myeloid leukemia

Balsat, M., Alcazer, V., Etienne, G., Huguet, F., Berger, M., Cayssials, E., Charbonnier, A., Escoffre-Barbe, M., Johnson-Ansah, H., Legros, L., et al. (2023) · Leukemia Research

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 5